EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Feasibility and Safety of Intravenous Sotalol Loading in Adult Patients With Atrial Fibrillation (DASH-AF)

Dhanunjaya Lakkireddy, Adnan Ahmed, Donita Atkins, Danish Bawa, Jalaj Garg, Jenny Bush, Rishi Charate, Sudha Bommana, Naga Venkata K Pothineni, Rajesh Kabra, Douglas Darden, Scott Koreber und 8 weitere

JACC: Clinical Electrophysiology · 2023

DOI: 10.1016/j.jacep.2022.11.026 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Clinical Electrophysiology, 2023. Verfasst von Dhanunjaya Lakkireddy und 19 weiteren Autor:innen. Beteiligte Einrichtung: Kansas City Heart Rhythm Institute, Overland Park, Kansas, USA. Electronic address: dlakkireddy@kchri.org. Hauptthemen laut MEDLINE: Sotalol, Atrial Fibrillation. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Inpatient initiation of sotalol is recommended owing to its proarrhythmic effects. OBJECTIVES: The DASH-AF (Feasibility and Safety of Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients With Atrial Fibrillation) trial evaluates the safety and feasibility of intravenous (IV) sotalol, achieving a steady state with maximum QTc prolongation within 6 hours instead of the traditional 5-dose inpatient oral (PO) titration. METHODS: DASH-AF is a prospective, nonrandomized, multicenter, open-label trial consisting of patients who underwent IV sotalol loading dose to initiate rapid oral therapy for atrial arrhythmias. IV dose was calculated based on the target oral dose as indicated by baseline QTc and renal function. Patients' QTc (in sinus) was measured via electrocardiography at 15-minute intervals and after IV loading completion. Patients were discharged 4 hours after first oral dose. All patients were monitored via mobile cardiac outpatient telemetry for 72 hours. The control group was composed of patients admitted for the traditional 5 PO doses. Safety outcomes were assessed in both groups. RESULTS: A total of 120 patients from 3 centers were enrolled from 2021 to 2022 in the IV loading group (compared with type of AF- and renal function-matched patients in the conventional PO loading cohort). This study demonstrated no significant change in ΔQTc in both groups, with a significantly lower number of patients requiring dose adjustment in the IV arm compared with the PO arm (4.1% vs 16.6%; P = 0.003). This led to potential cost savings of up to $3,500.68 per admission. CONCLUSIONS: The DASH-AF trial shows that rapid IV sotalol loading in atrial fibrillation/flutter patients for rhythm control is feasible and safe compared with conventional oral loading with significant cost reduction. (Feasibility and Safety of Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients With Atrial Fibrillation [DASH-AF]; NCT04473807).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SotalolAtrial FibrillationHumansAdultAnti-Arrhythmia AgentsProspective StudiesFeasibility Studies

Stichwörter der Autor:innen

IV sotalolMCOTQTcatrial fibrillationoral loadingtorsades de pointes

Substanzen

SotalolAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • Kansas City Heart Rhythm Institute, Overland Park, Kansas, USA. Electronic address: dlakkireddy@kchri.org.
  • Kansas City Heart Rhythm Institute, Overland Park, Kansas, USA.
  • Loma Linda University Medical Center, Loma Linda, California, USA.
  • Texas Cardiac Arrhythmia Institute, Austin, Texas, USA.
  • AltaThera Pharmaceuticals, Chicago, Illinois, USA.
  • Munson Medical Center, Traverse City, Michigan, USA.

Zitieren

APA

Lakkireddy, D., Ahmed, A., Atkins, D., Bawa, D., Garg, J., Bush, J., Charate, R., Bommana, S., Pothineni, N. V. K., Kabra, R., Darden, D., Koreber, S., Tummala, R., Vasamreddy, C., Park, P., Mohanty, S., Gopinathannair, R., Seo, B. W., Natale, A., & Kennedy, R. (2023). Feasibility and Safety of Intravenous Sotalol Loading in Adult Patients With Atrial Fibrillation (DASH-AF). JACC: Clinical Electrophysiology. https://doi.org/10.1016/j.jacep.2022.11.026

Vancouver

Lakkireddy D, Ahmed A, Atkins D, Bawa D, Garg J, Bush J, et al. Feasibility and Safety of Intravenous Sotalol Loading in Adult Patients With Atrial Fibrillation (DASH-AF). JACC: Clinical Electrophysiology. 2023. doi:10.1016/j.jacep.2022.11.026

BibTeX
@article{Lakkireddy2023,
  author = {Lakkireddy, Dhanunjaya and Ahmed, Adnan and Atkins, Donita and Bawa, Danish and Garg, Jalaj and Bush, Jenny and Charate, Rishi and Bommana, Sudha and Pothineni, Naga Venkata K and Kabra, Rajesh and Darden, Douglas and Koreber, Scott and Tummala, Rangarao and Vasamreddy, Chandrashekar and Park, Peter and Mohanty, Sanghamitra and Gopinathannair, Rakesh and Seo, B Woun and Natale, Andrea and Kennedy, Robert},
  title = {Feasibility and Safety of Intravenous Sotalol Loading in Adult Patients With Atrial Fibrillation (DASH-AF)},
  journal = {JACC: Clinical Electrophysiology},
  year = {2023},
  doi = {10.1016/j.jacep.2022.11.026}
}
Kostenlos starten →